Jessamy Tiffen YOU? Author Swipe

Last 10y

X and Y Differences in Melanoma Survival Between the Sexes Open

Peter Hersey, Hsin‐Yi Tseng, Sara Alavi, Jessamy Tiffen · 2024

Marked differences in survival from melanoma are noted between men and women that cannot be accounted for by behavioral differences. We and others have provided evidence that this difference may be due to increased expression of immune‐rel…

<span>BET</span> inhibition sensitizes innate checkpoint inhibitor resistant melanoma to <span>anti‐CTLA</span>‐4 treatment Open

Hsin‐Yi Tseng, Sara Alavi, Stuart Gallagher, Helen M. McGuire, Peter Hersey , et al. · 2024

Approximately 50% of melanoma patients fail to respond to immune checkpoint blockade (ICB), and acquired resistance hampers long‐term survival in about half of initially responding patients. Whether targeting BET reader proteins, implicate…

Correction: Overexpression of VIRMA confers vulnerability to breast cancers via the m6A-dependent regulation of unfolded protein response Open

Quintin Lee, Renhua Song, Dang Anh Vu Phan, Natalia Pinello, Jessica Tieng , et al. · 2023

Overexpression of VIRMA confers vulnerability to breast cancers via the m6A-dependent regulation of unfolded protein response Open

Quintin Lee, Renhua Song, Dang Anh Vu Phan, Natalia Pinello, Jessica Tieng , et al. · 2023

Supplementary Methods, Figure Legends 1-6 from Androgen Receptor and Nutrient Signaling Pathways Coordinate the Demand for Increased Amino Acid Transport during Prostate Cancer Progression Open

Qian Wang, Charles G. Bailey, Cynthia Ng, Jessamy Tiffen, Annora Thoeng , et al. · 2023

PDF file - 141K

Data from Androgen Receptor and Nutrient Signaling Pathways Coordinate the Demand for Increased Amino Acid Transport during Prostate Cancer Progression Open

Qian Wang, Charles G. Bailey, Cynthia Ng, Jessamy Tiffen, Annora Thoeng , et al. · 2023

l-Type amino acid transporters such as LAT1 and LAT3 mediate the uptake of essential amino acids. Here, we report that prostate cancer cells coordinate the expression of LAT1 and LAT3 to maintain sufficient levels of leucine needed for mTO…

Data from Androgen Receptor and Nutrient Signaling Pathways Coordinate the Demand for Increased Amino Acid Transport during Prostate Cancer Progression Open

Qian Wang, Charles G. Bailey, Cynthia Ng, Jessamy Tiffen, Annora Thoeng , et al. · 2023

l-Type amino acid transporters such as LAT1 and LAT3 mediate the uptake of essential amino acids. Here, we report that prostate cancer cells coordinate the expression of LAT1 and LAT3 to maintain sufficient levels of leucine needed for mTO…

Supplementary Figures 1-6, Table 1 from Androgen Receptor and Nutrient Signaling Pathways Coordinate the Demand for Increased Amino Acid Transport during Prostate Cancer Progression Open

Qian Wang, Charles G. Bailey, Cynthia Ng, Jessamy Tiffen, Annora Thoeng , et al. · 2023

PDF file - 1.5K

Supplementary Figures 1-6, Table 1 from Androgen Receptor and Nutrient Signaling Pathways Coordinate the Demand for Increased Amino Acid Transport during Prostate Cancer Progression Open

Qian Wang, Charles G. Bailey, Cynthia Ng, Jessamy Tiffen, Annora Thoeng , et al. · 2023

PDF file - 1.5K

Supplementary Methods, Figure Legends 1-6 from Androgen Receptor and Nutrient Signaling Pathways Coordinate the Demand for Increased Amino Acid Transport during Prostate Cancer Progression Open

Qian Wang, Charles G. Bailey, Cynthia Ng, Jessamy Tiffen, Annora Thoeng , et al. · 2023

PDF file - 141K

Liver-specific deletion of miR-181ab1 reduces liver tumour progression via upregulation of CBX7 Open

Jinbiao Chen, Yang Zhao, Fan Zhang, Jia Li, Jade A Boland , et al. · 2022

MiR-181 expression levels increased in hepatocellular carcinoma (HCC) compared to non-cancerous tissues. MiR-181 has been widely reported as a possible driver of tumourigenesis but also acts as a tumour suppressor. In addition, the miR-181…

Nicotinamide Inhibits T Cell Exhaustion and Increases Differentiation of CD8 Effector T Cells Open

Sara Alavi, Abdullah Al Emran, Hsin‐Yi Tseng, Jessamy Tiffen, Helen M. McGuire , et al. · 2022

One of the limitations of immunotherapy is the development of a state referred to as T cell exhaustion (TEx) whereby T cells express inhibitory receptors (IRs) and lose production of effectors involved in killing of their targets. In the p…

Overexpression of <i>VIRMA</i> Confers Vulnerability to Breast Cancers via the m <sup>6</sup>A-Dependent Regulation of Unfolded Protein Response Open

Quintin Lee, Renhua Song, Dang Anh Vu Phan, Natalia Pinello, Anni Su , et al. · 2022

Repurposing melanoma chemotherapy to activate inflammasomes in treatment of BRAF/MAPK inhibitor resistant melanoma Open

Farzana Ahmed, Hsin‐Yi Tseng, Antonio Ahn, Dilini Gunatilake, Sara Alavi , et al. · 2021

The development of resistance to treatments of melanoma is commonly associated with upregulation of the MAPK pathway and development of an undifferentiated state. Prior studies have suggested that melanoma with these resistance characteris…

Lysine Demethylases: Promising Drug Targets in Melanoma and Other Cancers Open

G. Punnia-Moorthy, Peter Hersey, Abdullah Al Emran, Jessamy Tiffen · 2021

Epigenetic dysregulation has been implicated in a variety of pathological processes including carcinogenesis. A major group of enzymes that influence epigenetic modifications are lysine demethylases (KDMs) also known as “erasers” which rem…

Sex bias of females in survival from cancer and infections. Is X the answer? Open

Abdullah Al Emran, Stuart Gallagher, Jessamy Tiffen, Peter Hersey · 2021

Major differences in survival of men and women from infectious diseases and cancers have been highlighted by death rates from COVID-19 infections. In cancer, attention has been focussed on differences in gene expression from X chromosomes …

Study of the Female Sex Survival Advantage in Melanoma—A Focus on X-Linked Epigenetic Regulators and Immune Responses in Two Cohorts Open

Abdullah Al Emran, Jérémie Nsengimana, G. Punnia-Moorthy, Ulf Schmitz, Stuart Gallagher , et al. · 2020

Background: Survival from melanoma is strongly related to patient sex, with females having a survival rate almost twice that of males. Many explanations have been proposed but have not withstood critical scrutiny. Prior analysis of differe…

Co‐targeting bromodomain and extra‐terminal proteins and <span>MCL1</span> induces synergistic cell death in melanoma Open

Hsin‐Yi Tseng, Jan Dreyer, Abdullah Al Emran, Dilini Gunatilake, Mehdi R Pirozyan , et al. · 2020

The treatment of melanoma has been markedly improved by the introduction of targeted therapies and checkpoint blockade immunotherapy. Unfortunately, resistance to these therapies remains a limitation. Novel anticancer therapeutics targetin…

Pretreatment Innate Cell Populations and CD4 T Cells in Blood Are Associated With Response to Immune Checkpoint Blockade in Melanoma Patients Open

Mehdi R Pirozyan, Helen M. McGuire, Abdullah Al Emran, Hsin‐Yi Tseng, Jessamy Tiffen , et al. · 2020

The development of changes in T cells, referred to as T cell exhaustion, has been suggested as a cause of primary or acquired resistance to immunotherapy by immune checkpoint blockade (ICB). A limited number of studies, largely performed o…

Do innate killing mechanisms activated by inflammasomes have a role in treating melanoma? Open

Abdullah Al Emran, Hsin‐Yi Tseng, Mikaela Coleman, Jessamy Tiffen, Stuart J Cook , et al. · 2020

Melanoma, as for many other cancers, undergoes a selection process during progression that limits many innate and adaptive tumor control mechanisms. Immunotherapy with immune checkpoint blockade overcomes one of the escape mechanisms but i…

Targeting DNA Methylation and EZH2 Activity to Overcome Melanoma Resistance to Immunotherapy Open

Abdullah Al Emran, Aniruddha Chatterjee, Euan J. Rodger, Jessamy Tiffen, Stuart Gallagher , et al. · 2019

Marked Global DNA Hypomethylation Is Associated with Constitutive PD-L1 Expression in Melanoma Open

Aniruddha Chatterjee, Euan J. Rodger, Antonio Ahn, Peter A. Stockwell, Matthew Parry , et al. · 2018

EZH2 as a mediator of treatment resistance in melanoma Open

Jessamy Tiffen, Stuart Gallagher, Hsin‐Yi Tseng, Fabian V. Filipp, Barbara Fazekas de St Groth , et al. · 2016

Summary Direct treatments of cancer such as chemotherapy, radiotherapy and targeted therapy have been shown to depend on recruitment of the immune system for their effectiveness. Recent studies have shown that development of resistance to …

Somatic Copy Number Amplification and Hyperactivating Somatic Mutations of EZH2 Correlate With DNA Methylation and Drive Epigenetic Silencing of Genes Involved in Tumor Suppression and Immune Responses in Melanoma Open

Jessamy Tiffen, Stephen Wilson, Stuart Gallagher, Peter Hersey, Fabian V. Filipp · 2016

Adenoma development in familial adenomatous polyposis and <i><span>MUTYH</span></i>‐associated polyposis: somatic landscape and driver genes Open

Mamunur Rashid, Andrej Fischer, Catherine H. Wilson, Jessamy Tiffen, Alistair G. Rust , et al. · 2015

Familial adenomatous polyposis ( FAP ) and MUTYH ‐associated polyposis ( MAP ) are inherited disorders associated with multiple colorectal adenomas that lead to a very high risk of colorectal cancer. The somatic mutations that drive adenom…

Histone Modifications, Modifiers and Readers in Melanoma Resistance to Targeted and Immune Therapy Open

Stuart Gallagher, Jessamy Tiffen, Peter Hersey · 2015

The treatment of melanoma has been revolutionized by new therapies targeting MAPK signaling or the immune system. Unfortunately these therapies are hindered by either primary resistance or the development of acquired resistance. Resistance…

Targeting of cytosolic phospholipase A2α impedes cell cycle re-entry of quiescent prostate cancer cells Open

Yao Mu, Chanlu Xie, Mei-Yee Kiang, Ying Teng, David G. Harman , et al. · 2015

Cell cycle re-entry of quiescent cancer cells has been proposed to be involved in cancer progression and recurrence. Cytosolic phospholipase A2α (cPLA2α) is an enzyme that hydrolyzes membrane glycerophospholipids to release arachidonic aci…

Targeting activating mutations of EZH2 leads to potent cell growth inhibition in human melanoma by derepression of tumor suppressor genes Open

Jessamy Tiffen, Dilini Gunatilake, Stuart Gallagher, Kavitha Gowrishankar, Anja Heinemann , et al. · 2015

The epigenetic modifier EZH2 is part of the polycomb repressive complex that suppresses gene expression via histone methylation. Activating mutations in EZH2 are found in a subset of melanoma that contributes to disease progression by inac…

Combining BET and HDAC inhibitors synergistically induces apoptosis of melanoma and suppresses AKT and YAP signaling Open

Anja Heinemann, Carleen Cullinane, Ricardo De Paoli‐Iseppi, James S. Wilmott, Dilini Gunatilake , et al. · 2015

Histone acetylation marks have an important role in controlling gene expression and are removed by histone deacetylases (HDACs). These marks are read by bromodomain and extra-terminal (BET) proteins and novel inhibitiors of these proteins …

Inducible but Not Constitutive Expression of PD-L1 in Human Melanoma Cells Is Dependent on Activation of NF-κB Open

Kavitha Gowrishankar, Dilini Gunatilake, Stuart Gallagher, Jessamy Tiffen, Helen Rizos , et al. · 2015

Monoclonal antibodies against immune checkpoint blockade have proven to be a major success in the treatment of melanoma. The programmed death receptor-1 ligand-1 (PD-L1) expression on melanoma cells is believed to have an inhibitory effect…

Fetching topic information...